Early preclinical studies targeting downstream elements of HIF-1α, such as VEGF, HGF, and FGF showed promise; however, clinical trials involving these growth factors yielded inconsistent results in PAD and CAD [147,148]. Here, HIF1A is linked to peripheral arterial disease.